Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samadhan G Kshirsagar

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cardiovascular & Hematological Agents in Medicinal Chemistry|October 21, 2014
Therapeutic potential of coagonists of glucagon and GLP-1Vishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Drug Development Research|January 22, 2021
Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stressAmit A Joharapurkar, Vishal J Patel, Samadhan G Kshirsagar, et al.
Current Molecular Pharmacology|February 13, 2019
Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid HormoneVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Current Research in Pharmacology and Drug Discovery|May 16, 2022
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive stateAmit A Joharapurkar, Vishal J Patel, Samadhan G Kshirsagar, et al.
Inflammopharmacology|November 23, 2024
Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammationVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
International Immunopharmacology|August 31, 2024
Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in miceVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Drug Development Research|April 7, 2025
HIF-Prolyl Hydroxylase Inhibitor Desidustat Increases Pyruvate Kinase Activity and Reduces Oxidative Stress in Red Blood Cells, Causes Erythrocytosis in Thalassaemic Mice, and Reduces Sickling in Sickle Cell Patient's BloodVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
British Journal of Pharmacology|April 29, 2017
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitusMukul R Jain, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
World Journal of Diabetes|July 11, 2018
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitusVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Toxicology and Applied Pharmacology|January 24, 2024
HIF-PHD inhibitor desidustat ameliorates iron deficiency anemiaVishal J Patel, Amit Joharapurkar, Samadhan G Kshirsagar, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cardiovascular & Hematological Agents in Medicinal Chemistry|October 21, 2014
Therapeutic potential of coagonists of glucagon and GLP-1Vishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Drug Development Research|January 22, 2021
Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stressAmit A Joharapurkar, Vishal J Patel, Samadhan G Kshirsagar, et al.
Current Molecular Pharmacology|February 13, 2019
Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid HormoneVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Current Research in Pharmacology and Drug Discovery|May 16, 2022
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive stateAmit A Joharapurkar, Vishal J Patel, Samadhan G Kshirsagar, et al.
Inflammopharmacology|November 23, 2024
Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammationVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
International Immunopharmacology|August 31, 2024
Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in miceVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Drug Development Research|April 7, 2025
HIF-Prolyl Hydroxylase Inhibitor Desidustat Increases Pyruvate Kinase Activity and Reduces Oxidative Stress in Red Blood Cells, Causes Erythrocytosis in Thalassaemic Mice, and Reduces Sickling in Sickle Cell Patient's BloodVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
British Journal of Pharmacology|April 29, 2017
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitusMukul R Jain, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
World Journal of Diabetes|July 11, 2018
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitusVishal J Patel, Amit A Joharapurkar, Samadhan G Kshirsagar, et al.
Toxicology and Applied Pharmacology|January 24, 2024
HIF-PHD inhibitor desidustat ameliorates iron deficiency anemiaVishal J Patel, Amit Joharapurkar, Samadhan G Kshirsagar, et al.
Pageof 2